ESI-GROUP/FAW-VW
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing intelligent simulation technology within the automotive industry. The ceremony, held at the FAW-VW R&D center in Changchun, Jilin Province, PRC, was officiated by Deng Guohui, Technical Development Director at FAW-VW, and Francis Griffiths, Executive Vice-President and Chief Revenue Officer at ESI Group.
The collaboration between ESI Group and FAW-VW TE aims to address the challenges posed by China's automotive safety regulations and drive industry innovation. Through this partnership, the two entities will aim to drive innovation and efficiency in intelligent simulation, and work towards establishing a localized automotive industry material database, thereby enhancing cooperation in advancing intelligent simulation technology across the industry. This collaborative effort is geared toward paving the way for a cleaner, safer, and more productive future.
Under the MoU, a material testing and intelligent simulation joint laboratory has been established, marking a significant step forward in intelligent simulation, innovation, and research within the automotive sector.
“With over 40 years of collaboration, ESI Group and VW Group have built strong ties, including a fruitful partnership with FAW-VW since 2007. This marks a significant milestone in our commitment to advancing virtual simulation technology in the automotive sector. Together with FAW-Volkswagen, we aim to drive innovation and efficiency in intelligent simulation, materials research and development,” declared Francis Griffiths, Executive Vice-President, Chief Revenue Officer at ESI Group.
"Today's milestone event celebrates not only two decades of fruitful collaboration but also embarks on a new era of innovation in automotive virtual simulation with ESI. This partnership signifies more than a formal agreement; it is a testament to our shared vision and commitment, aiming to pioneer intelligent simulation and materials research, setting new industry standards, and driving automotive safety and efficiency forward." declared Deng Guohui, Technical Development Director at FAW-VW.
During the ceremony, FAW-VW TE and ESI Group exchanged awards to honor their collaborative achievements in innovation. FAW-VW TE awarded ESI Group the prestigious "CAE Trusted Advisor" award, recognizing ESI's outstanding support in advancing virtual simulation technology in the automotive industry.
ESI Group reciprocated by presenting multiple global awards to FAW-VW's Technology Development team, including "Best Cooperation Partner" represented by Deng Guohui, Technical Development Director at FAW-VW and "Best Simulation Method Development Team" represented by Fu Xiaolong. Li Dapeng was also honored with the "'Virtual Performance Expert" award for their exceptional contributions. These accolades underscore the mutual respect, shared goals, and commitment of both companies to advancing automotive safety and efficiency through successful collaboration.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESI LinkedIn | Facebook | Twitter | YouTube
About FAW-Volkswagen
Established on February 6, 1991, FAW-Volkswagen Automotive Co., Ltd. (hereinafter referred to as FAW-Volkswagen) is a large-sized passenger auto manufacturer jointly managed by First Automotive Group Corporation, Volkswagen AG, Audi AG and Volkswagen (China) Investment Co., Ltd. It is the domestic first modern passenger auto manufacturer constructed according to the economic scale.
Through the development of around 30 years, FAW-Volkswagen has had the capacity layout in Changchun in the Northeast, Chengdu in the Southwest, Foshan in South China, Qingdao in East China and Tianjin in North China. It boasts eight professional manufacturing factories, namely No. 1 Car Factory, No. 2 Car Factory, No. 3 Car Factory, No. 4 Car Factory, No. 5 Car Factory, No. 6 Car Factory, Business Division of Power Assembly, and Punching Center.
Add: No. 5 Anqing Road, Auto Industry Development District, Changchun Jilin Province, PRC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401600103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom